Mirum Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
Mailing Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
Phone
650-667-4085
Fiscal Year End
1231
EIN
831281555
Financial Overview
FY2025
-$23.36M
Net Income
$314.69M
Stockholders' Equity
$296.68M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 10-K Annual financial report | February 25, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
Material Events
8-K
Acquisition
January 26, 2026
High Impact
- Dramatically expands Mirum's drug development pipeline and strengthens its standing in rare disease therapeutics.
- Acquisition of Bluejay's promising pipeline, including a key lead asset, aligns well with Mirum's established expertise in rare liver diseases.
Insider Trading
STRONG SELL
8 insiders
26 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.